GlassScriptPhysician profile
Logan M Richards
NPI 1235390634
$2,256.54
in general payments reported to CMS, 2019-2025
25 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $118 · 2021: $145 · 2022: $133 · 2023: $229 · 2024: $558 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $480.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $393.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $251.57 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $226.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $189.77 | 2022-2025 | Trelegy Ellipta |
| Abbvie INC. | $170.46 | 2021-2024 | |
| Pfizer INC. | $65.97 | 2019-2024 | |
| Astellas Pharma US INC | $55.93 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.88 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $40.01 | 2019-2021 | |
| Esperion Therapeutics, INC. | $37.72 | 2024-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $36.50 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $35.92 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $35.70 | 2019 | |
| Dexcom, INC. | $27.54 | 2024 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.37 | 2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $18.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.98 | 2019 | |
| Exact Sciences Corporation | $16.92 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $16.19 | 2021 | |
| Allergan, INC. | $14.44 | 2019 | |
| Genentech USA, INC. | $14.31 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.98 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.